The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Aberrant AKT activation drives well-differentiated liposarcoma
Open accessAbstract
Well-differentiated liposarcoma (WDLPS), one of the most common human sarcomas, is poorly responsive to radiation and chemotherapy, and the lack of animal models suitable for experimental analysis has seriously impeded functional investigation of its pathobiology and development of effective targeted therapies. Here, we show that zebrafish expressing constitutively active Akt2 in mesenchymal progenitors develop WDLPS that closely resembles the human disease. Tumor incidence rates were 8% in p53 wild-type zebrafish, 6% in p53 heterozygotes, and 29% in p53 -homozygous mutant zebrafish ( P = 0.013), indicating that aberrant Akt activation collaborates with p53 mutation in WDLPS pathogenesis. Analysis of primary clinical specimens of WDLPS, and of the closely related dedifferentiated liposarcoma (DDLPS) subtype, revealed immunohistochemical evidence of AKT activation in 27% of cases. Western blot analysis of a panel of cell lines derived from patients with WDLPS or DDLPS revealed robust AKT phosphorylation in all cell lines examined, even when these cells were cultured in serum-free media. Moreover, BEZ235, a small molecule inhibitor of PI3K and mammalian target of rapamycin that effectively inhibits AKT activation in these cells, impaired viability at nanomolar concentrations. Our findings are unique in providing an animal model to decipher the molecular pathogenesis of WDLPS, and implicate AKT as a previously unexplored therapeutic target in this chemoresistant sarcoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite their genetic complexity, these sarcomas share genomic alterations causing PI3K/Akt/mTOR and MAPK pathway activation”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [10]
Citations
Cites
The zebrafish book : a guide for the laboratory use of zebrafish (Danio rerio)
Westerfield, M. (1995) · Medical Entomology and Zoology · Cited by 6,813
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K. K., & Mertens, F. (2002) · Medical Entomology and Zoology · Cited by 2,073
Self-citationMaira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Kransdorf, M. J. (1995) · American Journal of Roentgenology · doi:10.2214/ajr.164.1.7998525 · Cited by 743
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Marsh, D. J., Kum, J. B., Lunetta, K. L., Bennett, M. J., Gorlin, R. J., Ahmed, S. F., Bodurtha, J., Crowe, C., Curtis, M. A., Dasouki, M., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1461 · Cited by 612
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Self-citationp53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach, F. S., Tokino, T., Meltzer, P. S., Burrell, M., Oliner, J., Smith, S., HILL, D. E., Sidransky, D., Kinzler, K. W., & Vogelstein, B. (1993) · PubMed · Cited by 533
Research works printed but not linked: 2
- AP Dei Tos, F Pedeutour, Atypical lipomatous tumor/well differentiated liposarcoma; Dedifferentiated liposarcoma. Pathology and Genetics of Tumors of Soft Tissue and Bone: World Health Organization Classification of Tumors., ed CDM Fletcher (IARC press, Lyon), pp. 35–39 (2002).
- 10.1002/(SICI)1096-9896(199701)181:1<14::AID-PATH730>3.0.CO;2-O · doi:10.1002/(sici)1096-9896(199701)181:1<14::aid-path730>3.0.co;2-o
Cited by
Laroche, A., Chaire, V., Algeo, M.-P., Karanian, M., Fourneaux, B., & Italiano, A. (2017) · Oncotarget · doi:10.18632/oncotarget.16345 · Cited by 38
Targeting eIF4A-dependent translation in genetically complex sarcoma
Kim, Y.-M., Mohan, P., Sehrawat, U., Seffar, E., De Queiroz, R. M., Chadalavada, K., Persaud, N., Okada, T., Kulkarni, A., Lin, J., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.192936
Metadata
- Authors
- Gutierrez, A., Snyder, E. L., Marino-Enriquez, A., Zhang, Y.-X., Sioletic, S., Kozakewich, E., Grebliunaite, R., Ou, W.-B., Sicinska, E., Raut, C. P., Demetri, G. D., Perez-Atayde, A. R., Wagner, A. J., Fletcher, J. A., Fletcher, C. D. M., & Look, A. T.
- Affiliations
- Department of Pediatric Oncology,
- Harvard University (US)
- Department of Pathology and
- The Ludwig Center at Dana-Farber/Harvard Cancer Center, and
- Department of Medical Oncology and Center for Molecular Oncologic Pathology,
- Brigham and Women's Hospital (US)
- Department of Pathology, Children's Hospital, Boston, MA 02115;
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-09-19
- Volume
- 108
- Issue
- 39
- Pages
- 16386-16391
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3182699
- OpenAlex
- W1982933649
- Cited by
- 58
- References
- 27
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 5 · 2012: 2
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- National Cancer Institute (K08CA154784, K08CA133103)
- National Center for Research Resources (UL1RR025758)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- well-differentiated liposarcoma, dedifferentiated liposarcoma, Akt activation, AKT2, TP53 mutation, zebrafish tumor model, mesenchymal progenitor cells, BEZ235, PI3K/mTOR inhibition, chemoresistance, therapeutic target, sarcoma pathogenesis
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Animals, Cell Cycle, Cell Differentiation, Enzyme Activation, Humans, Immunohistochemistry, Liposarcoma, Mutation, Zebrafish, Blotting, Western, Genes, p53, Apoptosis, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aberrant AKT activation drives well-differentiated liposarcoma. https://app.cochat.ai/papers/10.1073/pnas.1106127108
- The paper
- Gutierrez, A., Snyder, E. L., Marino-Enriquez, A., Zhang, Y.-X., Sioletic, S., Kozakewich, E., Grebliunaite, R., Ou, W.-B., Sicinska, E., Raut, C. P., Demetri, G. D., Perez-Atayde, A. R., Wagner, A. J., Fletcher, J. A., Fletcher, C. D. M., & Look, A. T. (2011). Aberrant AKT activation drives well-differentiated liposarcoma. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1106127108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.